Free Trial

InnovAge (NASDAQ:INNV) Sees Strong Trading Volume - Here's What Happened

InnovAge logo with Medical background

InnovAge Holding Corp. (NASDAQ:INNV - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 116,752 shares were traded during trading, an increase of 127% from the previous session's volume of 51,324 shares.The stock last traded at $3.77 and had previously closed at $3.77.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on INNV shares. KeyCorp began coverage on shares of InnovAge in a report on Friday, October 11th. They set a "sector weight" rating for the company. JPMorgan Chase & Co. restated an "underweight" rating and issued a $5.00 target price on shares of InnovAge in a research report on Tuesday, December 17th.

View Our Latest Stock Report on INNV

InnovAge Stock Down 1.1 %

The business's 50 day moving average price is $4.17 and its 200-day moving average price is $5.32. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.21 and a current ratio of 1.21. The firm has a market capitalization of $505.27 million, a PE ratio of -31.08 and a beta of 0.37.

InnovAge (NASDAQ:INNV - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.04) EPS for the quarter, hitting analysts' consensus estimates of ($0.04). The company had revenue of $205.14 million for the quarter, compared to analysts' expectations of $203.35 million. InnovAge had a negative return on equity of 5.68% and a negative net margin of 2.03%. During the same period in the prior year, the firm earned ($0.08) earnings per share. As a group, equities research analysts forecast that InnovAge Holding Corp. will post -0.06 earnings per share for the current year.

Institutional Trading of InnovAge

Several hedge funds have recently modified their holdings of the stock. Barclays PLC boosted its position in shares of InnovAge by 289.0% during the 3rd quarter. Barclays PLC now owns 25,614 shares of the company's stock worth $154,000 after acquiring an additional 19,029 shares in the last quarter. State Street Corp boosted its holdings in InnovAge by 1.2% in the third quarter. State Street Corp now owns 344,905 shares of the company's stock valued at $2,069,000 after purchasing an additional 4,218 shares in the last quarter. Geode Capital Management LLC increased its stake in InnovAge by 5.5% in the third quarter. Geode Capital Management LLC now owns 527,955 shares of the company's stock valued at $3,168,000 after purchasing an additional 27,304 shares during the last quarter. Renaissance Technologies LLC raised its holdings in InnovAge by 3.1% during the second quarter. Renaissance Technologies LLC now owns 136,400 shares of the company's stock worth $677,000 after purchasing an additional 4,100 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of InnovAge by 3.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,531 shares of the company's stock valued at $993,000 after buying an additional 6,153 shares in the last quarter. 12.26% of the stock is currently owned by institutional investors and hedge funds.

About InnovAge

(Get Free Report)

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in InnovAge Right Now?

Before you consider InnovAge, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InnovAge wasn't on the list.

While InnovAge currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

How To Invest in Crypto as A Complete BEGINNER in 2025
3 AI Bargain Stocks to BUY NOW After the DeepSeek Crash
NVIDIA Stock Under Pressure: DeepSeek and the AI Tech War

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines